Multiple research projects - including a 2006 study conducted at the University of North Carolina at Chapel Hill - have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help...
New data suggest that breast cancer patients with HER2- and basal-molecular subtypes are more likely to respond to neoadjuvant chemotherapy than patients with luminal-type molecular subtype characteristics. The findings were released at the 32nd Annual San Antonio Breast Cancer Symposium...